WRAIR-PAM-CF1
AXP000235.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Originator
- Walter Reed Army Institute of Research
- Sponsor
- National Institute of Allergy and Infectious Diseases
Names
| Name | Type | Source |
|---|---|---|
| WRAIR-PAM-CF1 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Pseudomonas aeruginosa bacteriophage (cocktail)
- Replication
- replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05453578 | A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa | Completed | Phase 1/2 | 2022-10-03 | 2025-04-10 | 73 | Bacterial Disease Carrier; Cystic Fibrosis |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42937369 | Comparative plaque- and liquid-based phage susceptibility testing of Pseudomonas aeruginosa isolates in a cystic fibrosis randomized clinical trial. | Journal of clinical microbiology | 2026 | name in abstract: WRAIR-PAM-CF1 |
| PMID 36578069 | Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial. | Trials | 2022 | cited by trial NCT05453578 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40632642 | Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials. | Expert opinion on investigational drugs | 2025 | name in abstract: WRAIR-PAM-CF1 |
Notes
Anti-Pseudomonas aeruginosa phage cocktail made at the Walter Reed Army Institute of Research, given as a single dose in a phase 1b/2 trial in cystic fibrosis (NCT05453578, completed).
How to cite
WRAIR-PAM-CF1 (AXP000235.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000235.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.